In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Biogen Idec Taps Exelixis' Scangos To Be New CEO

Executive Summary

Exelixis’s long-time CEO George Scangos, PhD, is taking the the helm of Biogen Idec. The move is counterintuitive, both for the commercial stage Biogen and for Scangos, whose career has largely been focused on research and early development and free of activist shareholder pressure.

You may also be interested in...



Biogen Idec Charts A New Course

Thanks to a November restructuring that refocused the company around its historic strength in neurology and the hiring of two critical executives, Biogen believes it can grow beyond its warhorses Avonex and Tysabri

Biogen Idec Charts A New Course

Thanks to a November restructuring that refocused the company around its historic strength in neurology and the hiring of two critical executives, Biogen believes it can grow beyond its warhorses Avonex and Tysabri

Exelixis Puts '184 Back in Spotlight With "Dramatic" Prostate Cancer Results

In interim Phase II data, the unpartnered drug reverses bone lesions in metastatic prostate cancer patients.

Related Content

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

IV003522

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel